Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Regenicin Inc. (RGIN : OTC)

• Company Description    Regenicin, Inc is a development stage biotechnology company primarily focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company's product candidate includes PermaDerm that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns and wounds. The candidate uses biomedical polymer to act as a connective agent in the skin generation process. The Company's prime focus is development of therapeutics in the areas of diabetes, chronic wounds, including ulcers, adult stem cell therapies and reconstructive surgery applications. Regenicin, Inc is headquartered in New York, New York. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 1,850 shares Shares Outstanding: 153.77 (millions) Market Capitalization: $0.31 (millions) Beta: 0.67 52 Week High: $0.03 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -86.11% -84.36% 12 Week -85.51% -84.07% Year To Date -80.00% -75.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10 HIGH COURT - LITTLE FALLS,NJ 07424 USA ph: 973-557-8914 fax: - None http://www.regenicin.com

• General Corporate Information    Officers Randall McCoy - Chief Executive Officer; President and Director John J. Weber - Principal Financial and Accounting Officer; and Di J. Roy Nelson - Chief Science Officer Craig Eagle - Director Craig Eagle - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75887Q102 SIC: 3841 Fiscal Year Fiscal Year End: September Last Reported Quarter: 12/01/21 Next Expected EPS Date: 05/23/22 Share - Related Items Shares Outstanding: 153.77 Most Recent Split Date: (:1) Beta: 0.67 Market Capitalization: $0.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/23/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - -13,783.47 09/30/21 - -15,931.94 Current Ratio 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Quick Ratio 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - -0.03 09/30/21 - -0.03 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©